A clinical trial targeting LOXL2 using the monoclonal antibody simtuzumab, found no benefit regarding survival75, although limited data about its bioavailability and target engagement in IPF are known. This evidence concerns the gene LOXL2 and idiopathic pulmonary fibrosis.